-
公开(公告)号:US20100029734A1
公开(公告)日:2010-02-04
申请号:US12436210
申请日:2009-05-06
IPC分类号: A61K31/4184 , G01N33/574 , A61K31/41 , A61K31/401 , A61K31/165 , A61P35/00
CPC分类号: G01N33/57415 , G01N2333/515 , G01N2333/723 , G01N2800/52
摘要: A method for selecting a breast cancer patient for therapy with an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, comprises (a) determining whether the cancer comprises a tumor that is estrogen receptor positive (ER+) and (b) selecting the patient for such therapy only if the cancer is determined to comprise an ER+ tumor. A method for treating breast cancer in a patient further comprises (c) administering to the patient, if so selected, an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A method for treating a breast tumor in a patient having SERM-resistant ER+ breast cancer comprises administering to the patient an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A therapeutic combination useful in treatment of a breast tumor comprises an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, and a second agent that comprises (a) an aromatase inhibitor or (b) an estrogen receptor modulator or antagonist.
摘要翻译: 选择用于减少血管紧张素II生成剂(例如ACE抑制剂或肾素抑制剂)治疗的乳腺癌患者的方法包括(a)确定癌症是否包含雌激素受体阳性(ER +)和( b)仅当确定癌症包括ER +肿瘤时,才选择患者进行此类治疗。 用于治疗患者乳腺癌的方法进一步包括(c)如果这样选择,向患者施用减少血管紧张素II生成的试剂,例如ACE抑制剂或肾素抑制剂。 在具有SERM抗性ER +乳腺癌的患者中治疗乳腺肿瘤的方法包括向患者施用减少血管紧张素II产生的药物,例如ACE抑制剂或肾素抑制剂。 可用于治疗乳腺肿瘤的治疗组合包括减少血管紧张素II的产生的药物,例如ACE抑制剂或肾素抑制剂,以及第二药剂,其包含(a)芳香酶抑制剂或(b)雌激素受体调节剂或 拮抗剂。
-
公开(公告)号:US20080132474A1
公开(公告)日:2008-06-05
申请号:US11935870
申请日:2007-11-06
IPC分类号: G01N33/574 , A61K31/56 , A61K31/4184 , A61P35/00 , A61K31/41 , A61K31/135
CPC分类号: G01N33/57415
摘要: A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+ tumor. A method for treating breast cancer in a female patient further comprises (c) administering to the patient, if so selected, an AT1 receptor antagonist according to a regimen effective to reduce growth, invasiveness and/or metastasis of the tumor.
摘要翻译: 用于选择AT>受体拮抗剂治疗的女性乳腺癌患者的方法包括(a)确定癌症是否包括ER +和/或PR +的肿瘤; 和(b)仅当确定癌症包含ER +和/或PR +肿瘤时才选择患者进行AT 1受体拮抗剂治疗。 用于治疗女性患者乳腺癌的方法还包括(c)根据有效减少生长,侵袭和/或转移的方案向患者施用(如果这样选择)AT 1受体拮抗剂 的肿瘤。
-
公开(公告)号:US20090012052A1
公开(公告)日:2009-01-08
申请号:US12100053
申请日:2008-04-09
IPC分类号: A61K31/4184 , A61K31/135 , A61K31/56 , A61P35/00 , A61K31/41
CPC分类号: G01N33/57415 , A61K31/135 , A61K31/41 , A61K31/4184
摘要: A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+ tumor. A method for treating breast cancer in a female patient further comprises (c) administering to the patient, if so selected, an AT1 receptor antagonist according to a regimen effective to reduce growth, invasiveness and/or metastasis of the tumor.
摘要翻译: 用于选择女性乳腺癌患者AT1受体拮抗剂治疗的方法包括(a)确定癌症是否包括ER +和/或PR +的肿瘤; 和(b)仅当确定癌症包含ER +和/或PR +肿瘤时,才选择AT1受体拮抗剂治疗患者。 用于治疗女性患者乳腺癌的方法还包括(c)根据有效降低肿瘤生长,侵袭和/或转移的方案,向患者施用AT1受体拮抗剂(如果这样选择)。
-
-